Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates

• Published in: Pharmacogenetics and genomics Vol. 17; no. 12; p. 1017
• Main Authors: Udomuksorn, Wandee, Elliot, David J, Lewis, Benjamin C, Mackenzie, Peter I, Yoovathaworn, Krongtong, Miners, John O
• Format: Journal Article
• Language: English
• Published: United States 01.12.2007
• Subjects: Amino Acid Substitution; Bilirubin - metabolism; Cell Line; Crigler-Najjar Syndrome - enzymology; Crigler-Najjar Syndrome - genetics; Estradiol - metabolism; Gilbert Disease - enzymology; Gilbert Disease - genetics; Glucuronides - metabolism; Glucuronosyltransferase - genetics; Glucuronosyltransferase - metabolism; Humans; Hymecromone - analogs & derivatives; Hymecromone - metabolism; Kinetics; Mutagenesis, Site-Directed; Naphthols - metabolism; Pharmacogenetics; Point Mutation; Recombinant Proteins - genetics; Recombinant Proteins - metabolism; Substrate Specificity
• ISSN: 1744-6872
• DOI: 10.1097/FPC.0b013e328256b1b6

UGT1A1 coding region mutations, including UGT1A1*6 (G71R), UGT1A1*7 (Y486D), UGT1A1*27 (P229Q) and UGT1A1*62 (F83L), have been linked to Gilbert syndrome in Asian populations, whereas homozygosity for UGT1A1*7 is associated with the Crigler-Najjar syndrome type II. This work compared the effects of (a) the individual UGT1A1 mutations on the glucuronidation kinetics bilirubin, beta-estradiol, 4-methylumbelliferone (4MU) and 1-naphthol (1NP), and (b) the Y486 mutation, which occurs in the conserved carboxyl terminal domain of UGT1A enzymes, on 4MU, 1NP and naproxen glucuronidation by UGT1A3, UGT1A6 and UGT1A10. Mutant UGT1A cDNAs were generated by site-directed mutagenesis and the encoded proteins were expressed in HEK293 cells. The glucuronidation kinetics of each substrate with each enzyme were characterized using specific high-performance liquid chromatography (HPLC) methods. Compared with wild-type UGT1A1, in-vitro clearances for bilirubin, beta-estradiol, 4MU and 1NP glucuronidation by UGT1A1*6 and UGT1A1*27 were reduced by 34-74%, most commonly as a result of a reduction in Vmax. However, the magnitude of the decrease in the in-vitro clearances varied from substrate to substrate with each mutant. The glucuronidation activities of UGT1A1*7 and UGT1A1*62 were reduced by >95%. Introduction of the Y486D mutation essentially abolished UGT1A6 and UGT1A10 activities, and resulted in 60-90% reductions in UGT1A3 in-vitro clearances. The glucuronidation of all UGT1A1 substrates is likely to be impaired in subjects carrying the UGT1A1*6 and UGT1A1*62 alleles, although the reduction in metabolic clearance might vary with the substrate. The Y486D mutation appears to greatly reduce most, but not all, UGT1A activities.